Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lumosa Therapeutics CoROCO:6535 -0.23%66 Cyclically Adjusted PS Ratio is 178.98 as of Aug. 04, 2026, which is 53% below its 10-year median of 381.00. GuruFocus rates ROCO:6535 with a GF Score™ of 66/100 and a GF Value™ of NT$127.81 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 538 Biotechnology companies, Lumosa Therapeutics Co ranks worse than 96.84% on this metric.
The historical rank and industry rank for Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio or its related term are showing as below:
ROCO:6535'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 183.16 Med: 381 Max: 750
Current: 183.16
During the past years, Lumosa Therapeutics Co's highest Cyclically Adjusted PS Ratio was 750.00. The lowest was 183.16. And the median was 381.00.
ROCO:6535's Cyclically Adjusted PS Ratio is ranked worse than 96.84% of 538
companies
in the Biotechnology industry
Industry Median: 5.5
vs ROCO:6535: 183.16
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Lumosa Therapeutics Co's adjusted revenue per share data for the three months ended in Mar. 2026 was NT$0.027. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is NT$0.49 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Lumosa Therapeutics Co (ROCO:6535) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Lumosa Therapeutics Co Cyclically Adjusted PS Ratio Related Terms
Lumosa Therapeutics Co Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumosa Therapeutics Co Cyclically Adjusted PS Ratio Chart
ROCO:6535 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumosa Therapeutics Co Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio falls into.
Lumosa Therapeutics Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 178.98 mean?
Lumosa Therapeutics Co (ROCO:6535) has a Cyclically Adjusted PS Ratio of 178.98 as of Aug. 04, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lumosa Therapeutics Co and its competitors. This is 53% below median its historical median of 381.00. Over the past decade, Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio has ranged from 183.16 to 750.00. According to the industry distribution chart, Lumosa Therapeutics Co ranks #521 out of 538 companies in the Biotechnology industry, placing it in the top 96.8%.
Is Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio too high?
Lumosa Therapeutics Co's current Cyclically Adjusted PS Ratio of 178.98 is 53% below median its 10-year median of 381.00. Over the past 10 years, this metric has ranged from a low of 183.16 to a high of 750.00. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.50. Lumosa Therapeutics Co's value of 178.98 is 3154.2% above this industry median. Based on the distribution chart, Lumosa Therapeutics Co ranks #521 out of 538 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lumosa Therapeutics Co has a GF Score™ of 66/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lumosa Therapeutics Co's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lumosa Therapeutics Co ranks #521 out of 538 companies for Cyclically Adjusted PS Ratio. This places Lumosa Therapeutics Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.50. Lumosa Therapeutics Co's value of 178.98 is 3154.2% above this benchmark. Historically, Lumosa Therapeutics Co's own Cyclically Adjusted PS Ratio has ranged from 183.16 to 750.00 over the past decade. While the company's 10-year median is 381.00 vs. the industry median of 5.50, Lumosa Therapeutics Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.50, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lumosa Therapeutics Co's current Cyclically Adjusted PS Ratio of 178.98 is 3154.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Lumosa Therapeutics Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lumosa Therapeutics Co's current Cyclically Adjusted PS Ratio is 178.98, which is 53% below median its own 10-year median of 381.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumosa Therapeutics Co stock overvalued right now?
Based on GuruFocus' analysis, Lumosa Therapeutics Co (ROCO:6535) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$127.81, compared to a current price of NT$87.70 — trading 31.4% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 178.98, which is 53% below median its 10-year median of 381.00 and 3154.2% above the Biotechnology industry median of 5.50. Lumosa Therapeutics Co's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Lumosa Therapeutics Co (ROCO:6535), the current Cyclically Adjusted PS Ratio is 178.98 as of Aug. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumosa Therapeutics Co (ROCO:6535) Overvalued in 2026?
Based on GuruFocus' analysis, Lumosa Therapeutics Co stock appears to be undervalued.
The current stock price of NT$87.70 is trading 31.4% below its estimated GF Value™ of NT$127.81.
GuruFocus considers Lumosa Therapeutics Co to be Significantly Undervalued.
Key valuation signals for ROCO:6535:
Cyclically Adjusted PS Ratio: 178.98 (53% below median its 10-year median of 381.00)
GF Value™: NT$127.81 vs. price of NT$87.70 (31.4% below fair value)
Industry Position: 3154.2% above the Biotechnology median (#521 of 538)
No single metric tells the full story. See the ROCO:6535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of oncology and Neuroscience. Geographically, it derives a majority of its revenue from Taiwan and also has a presence in Asia, and America. The product pipeline of the company is Neuroscience, which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology, including LT 2003 for Solid Tumor. It generates revenue from sales of goods.
66GF Score
Get the complete analysis for ROCO:6535
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6535 has been successfully added to your 
